Evidence map›Paper›PMID 29377268›Full record

ArticleClinical transplantation2018

Elevated donor plasminogen activator inhibitor-1 levels and the risk of primary graft dysfunction.

Barbara C S Hamilton, Gabriela R Dincheva, Hanjing Zhuo, Jeffrey A Golden, Marek Brzezinski, Jonathan P Singer, Michael A Matthay, Jasleen Kukreja

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical transplantation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Barbara C S HamiltonDepartment of Surgery, University of California, San Francisco, CA, USA.ORCID 0000-0002-5498-3378
Gabriela R DinchevaDepartment of Surgery, University of California, San Francisco, CA, USA.
Hanjing ZhuoDepartment of Surgery, University of California, San Francisco, CA, USA.
Jeffrey A GoldenDepartment of Surgery, University of California, San Francisco, CA, USA.
Marek BrzezinskiDepartment of Surgery, University of California, San Francisco, CA, USA.
Jonathan P SingerDepartment of Surgery, University of California, San Francisco, CA, USA.
Michael A MatthayDepartment of Surgery, University of California, San Francisco, CA, USA.
Jasleen KukrejaDepartment of Surgery, University of California, San Francisco, CA, USA.
University of California, San Francisco · US

Funding

The GOLD Study: Goal of Open Lung Ventilation in DonorsR01HL126176 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI WARE, LORRAINE B · 2015 to 2020
$2.8M
NHLBI NIH HHS R01 HL126176
6 · The paper itself

Abstract

Primary graft dysfunction (PGD) following lung transplantation is associated with elevated recipient plasma levels of plasminogen activator inhibitor-1 (PAI-1) and the receptor for advanced glycation end products (RAGE). However, the significance of these biomarkers in the donor plasma is uncertain. We hypothesized that elevated donor plasma levels of PAI-1 and RAGE would be associated with recipient PGD. We carried out a prospective unmatched case-control study of double-lung transplant recipients between May 2014 and September 2015. We compared donor plasma levels of PAI-1 and RAGE using rank-sum tests and t tests, in 12 recipients who developed PGD grade 2 or 3 within 72 hours postoperatively with 13 recipients who did not. Recipients who developed PGD had higher donor plasma levels of PAI-1 than recipients who did not (median 2.7 ng/mL vs 1.4; P = .03). Recipients with PGD also had numerically higher donor plasma levels of RAGE than recipients without PGD, although this difference did not achieve statistical significance (median 1061 pg/mL vs 679; P = .12). Systemic inflammatory responses in the donor, as reflected by elevated plasma levels of PAI-1, may contribute to the risk of developing PGD. Rapid biomarker assessment of easily available plasma samples may assist in donor lung selection and risk stratification.

Indexed as

BiomarkersCase-Control StudiesFemaleFollow-Up StudiesHumansLung DiseasesLung TransplantationMaleMiddle AgedPilot ProjectsPlasminogen Activator Inhibitor 1Postoperative ComplicationsPrimary Graft DysfunctionPrognosisProspective StudiesRisk FactorsBiomarkersPlasminogen Activator Inhibitor 1SERPINE1 protein, humanbiomarkerdonorlung transplantationplasminogen activator inhibitor 1primary graft dysfunction

Identifiers

PMID29377268
PMCPMC5924447
OpenAlexW2789677369

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.